Your browser is no longer supported. Please, upgrade your browser.
ANAB AnaptysBio, Inc. monthly Stock Chart
ANAB [NASD]
AnaptysBio, Inc.
Index- P/E- EPS (ttm)-3.49 Insider Own0.40% Shs Outstand27.54M Perf Week12.20%
Market Cap433.20M Forward P/E- EPS next Y-4.07 Insider Trans0.00% Shs Float26.72M Perf Month43.00%
Income-94.10M PEG- EPS next Q-1.22 Inst Own- Short Float11.92% Perf Quarter-65.25%
Sales5.00M P/S86.64 EPS this Y-64.40% Inst Trans-3.68% Short Ratio3.43 Perf Half Y-76.60%
Book/sh15.56 P/B1.01 EPS next Y0.20% ROA-19.40% Target Price37.11 Perf Year-77.68%
Cash/sh15.29 P/C1.03 EPS next 5Y- ROE-20.60% 52W Range10.00 - 83.10 Perf YTD-75.34%
Dividend- P/FCF- EPS past 5Y-53.90% ROI-13.50% 52W High-81.07% Beta-
Dividend %- Quick Ratio14.30 Sales past 5Y-1.80% Gross Margin- 52W Low57.30% ATR1.58
Employees78 Current Ratio14.30 Sales Q/Q- Oper. Margin- RSI (14)42.28 Volatility6.39% 6.07%
OptionableYes Debt/Eq0.01 EPS Q/Q-73.50% Profit Margin- Rel Volume0.69 Prev Close16.18
ShortableYes LT Debt/Eq0.00 EarningsNov 21 BMO Payout- Avg Volume928.26K Price15.73
Recom2.90 SMA2019.68% SMA50-37.14% SMA200-69.66% Volume640,110 Change-2.78%
Nov-08-19Downgrade Wedbush Outperform → Neutral
Nov-08-19Downgrade SunTrust Buy → Hold
Nov-08-19Downgrade JP Morgan Overweight → Underweight $109 → $17
Nov-08-19Downgrade Jefferies Buy → Hold $12
Jun-21-19Downgrade Stifel Buy → Hold $124 → $74
Jun-21-19Downgrade Credit Suisse Outperform → Neutral $137 → $79
Dec-20-18Initiated H.C. Wainwright Buy $126
Nov-21-18Initiated JP Morgan Overweight $115
Jul-19-18Initiated Credit Suisse Outperform $104
Apr-04-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-27-18Reiterated Stifel Buy $139 → $152
Mar-06-18Reiterated Stifel Buy $130 → $139
Feb-15-18Reiterated SunTrust Buy $115 → $162
Jan-23-18Reiterated Credit Suisse Outperform $85 → $135
Nov-15-17Initiated SunTrust Buy $115
Nov-09-17Initiated Jefferies Buy $101
Oct-11-17Reiterated RBC Capital Mkts Outperform $40 → $79
Sep-15-17Initiated RBC Capital Mkts Outperform $40
Jul-11-17Initiated Robert W. Baird Outperform $36
Feb-21-17Initiated Wedbush Outperform $28
Dec-13-19 10:01AM  Hedge Funds Couldnt Dump AnaptysBio, Inc. (ANAB) Fast Enough Insider Monkey
Nov-24-19 04:18PM  Analysts See These 2 Falling Knives Rebounding Within a Year GuruFocus.com
Nov-11-19 10:53AM  These Are The Winners Of The Inaugural WeTrader Paper Trading Competition Benzinga
08:55AM  AnaptysBio Enters Oversold Territory Zacks
Nov-08-19 04:21PM  Why This Biotech Stock Just Crashed 72% To Its Lowest-Ever Point Investor's Business Daily -71.85%
10:18AM  Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72% Bloomberg
09:25AM  AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:53AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Nov. 8, 2019: DIS, STMP, ANAB, GDOT, MCD Benzinga
08:05AM  AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates GlobeNewswire
08:00AM  AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint GlobeNewswire
Nov-07-19 10:30AM  Earnings Preview: AnaptysBio, Inc. (ANAB) Q3 Earnings Expected to Decline Zacks
Oct-31-19 11:06AM  Top Ranked Momentum Stocks to Buy for October 31st Zacks
Oct-26-19 12:44PM  Here is What Hedge Funds Think About AnaptysBio, Inc. (ANAB) Insider Monkey
Oct-20-19 08:15AM  Did Changing Sentiment Drive AnaptysBio's (NASDAQ:ANAB) Share Price Down A Worrying 53%? Simply Wall St.
Oct-03-19 08:39AM  AnaptysBio (ANAB) Looks Good: Stock Adds 8.1% in Session Zacks
Oct-02-19 07:17AM  The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data Benzinga +8.10%
Oct-01-19 04:10PM  Investors Yawn As Biotech Puts Up Positive Test Results For 2 Patients Investor's Business Daily -10.40%
02:53PM  Wedbush: Investors Largely Underappreciating AnaptysBio Benzinga
11:18AM  AnaptysBio Shares Drop Amid Questions About Phase II Participation Numbers TheStreet.com
Sep-30-19 04:15PM  AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis GlobeNewswire
Sep-27-19 06:30AM  AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Aug-21-19 10:48AM  Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly? Simply Wall St.
Aug-20-19 04:46PM  Here's Why AnaptysBio Shares Are Slipping Today Motley Fool -13.63%
Aug-10-19 07:56PM  AnaptysBio Prepares for a Potential Gear Shift Motley Fool
Aug-08-19 04:15PM  AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates GlobeNewswire
Aug-06-19 06:30AM  AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference GlobeNewswire
Jun-21-19 04:15PM  Regeneron And Sanofi Tried To Outperform Themselves And Couldn't Investor's Business Daily -11.61%
02:47PM  Here's Why AnaptysBio Shares Are Sliding Today Motley Fool
08:31AM  Does The AnaptysBio, Inc. (NASDAQ:ANAB) Share Price Tend To Follow The Market? Simply Wall St.
08:29AM  Does AnaptysBio, Inc. (NASDAQ:ANAB) Have A Volatile Share Price? Simply Wall St.
Jun-05-19 07:00AM  AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma GlobeNewswire
May-28-19 06:55AM  AnaptysBio to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-08-19 03:41PM  AnaptysBio Started 2019 Quiet as a Ninja Motley Fool
May-07-19 04:15PM  AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates GlobeNewswire
May-01-19 11:53AM  Is AnaptysBio, Inc. (ANAB) A Good Stock To Buy? Insider Monkey
06:30AM  AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference GlobeNewswire
Apr-17-19 09:00AM  What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock Zacks -5.07%
Apr-04-19 05:43AM  Will AnaptysBio Continue to Surge Higher? Zacks
Mar-12-19 01:26PM  Introducing AnaptysBio (NASDAQ:ANAB), The Stock That Dropped 42% In The Last Year Simply Wall St. +8.95%
Mar-06-19 10:09AM  All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy Zacks -7.84%
Mar-04-19 06:30AM  AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-28-19 05:45AM  AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates GlobeNewswire
Jan-02-19 06:30AM  AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference GlobeNewswire
Dec-13-18 04:18AM  Hedge Funds Are Crazy About AnaptysBio, Inc. (ANAB) Insider Monkey
Nov-26-18 08:00AM  Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-09-18 05:21PM  Here's Why AnaptysBio, Inc. Slipped on Friday Motley Fool -10.75%
03:37PM  Short Seller's Case on AnaptysBio: Bad Data and CEO Resume Snafu Bloomberg
01:28PM  AnaptysBio Inc. Sets Up More Shots on Goal in the Third Quarter Motley Fool
Nov-08-18 04:15PM  AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates GlobeNewswire -6.04%
Nov-05-18 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-11-18 12:51PM  Here's Why AnaptysBio Rose 12.6% in September Motley Fool
Oct-08-18 07:30AM  Research Report Identifies AnaptysBio, Imperial Oil, Norbord, 3D, Apple Hospitality REIT, and Pinnacle Foods with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-28-18 04:05PM  AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters Option GlobeNewswire
Sep-25-18 07:49PM  AnaptysBio Announces Pricing of Public Offering of Common Stock GlobeNewswire -7.35%
08:54AM  AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session Zacks
Sep-24-18 04:01PM  AnaptysBio Announces Proposed Public Offering of Common Stock GlobeNewswire +9.86%
12:41PM  Here's Why AnaptysBio Inc Rose as Much as 18.5% Today Motley Fool
06:30AM  AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma GlobeNewswire
Sep-10-18 08:56AM  Options Traders Expect Huge Moves in AnaptysBio (ANAB) Stock Zacks
Aug-07-18 06:54PM  AnaptysBio Inc.'s Lead Candidate Gets New Priorities Motley Fool
07:50AM  AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:30AM  AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates GlobeNewswire
Aug-06-18 06:30AM  AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-25-18 06:02PM  Why AnaptysBio Rose 10.5% Today Motley Fool +10.53%
07:50AM  Report: Exploring Fundamental Drivers Behind Martin Midstream Partners, AnaptysBio, Bright Horizons Family Solutions, Masonite International, Digimarc, and Cohu New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jul-23-18 08:39AM  Implied Volatility Surging for AnaptysBio (ANAB) Stock Options Zacks
Jun-07-18 02:00PM  Soaring No-Name Stocks Signal a Market Top Investopedia
May-30-18 06:30AM  AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-29-18 08:30AM  AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress GlobeNewswire
May-18-18 08:25AM  Market Trends Toward New Normal in Castlight Health, inc, Marriot Vacations Worldwide, AnaptysBio, Compass Diversified, Triumph, and Asbury Automotive Group Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-09-18 03:48PM  AnaptysBio Sets the Stage for an Eventful Year Motley Fool
May-08-18 04:15PM  AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates GlobeNewswire
May-01-18 06:30AM  AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress GlobeNewswire
Apr-27-18 06:30AM  AnaptysBio To Participate in Upcoming Investor Conferences GlobeNewswire +6.22%
Apr-05-18 04:55PM  Here's What Pressured AnaptysBio Inc. Again Today Motley Fool -7.45%
Apr-02-18 06:52PM  Is This Why AnaptysBio Inc. Fell on Monday? Motley Fool -9.67%
Mar-29-18 07:50AM  Blog Exposure - Nabriva Therapeutics Collaborated with Roivant to Commercialize Lefamulin in Greater China ACCESSWIRE
Mar-27-18 04:07PM  Why These Biotechs Diverged On AnaptysBio's Peanut Allergy Study Investor's Business Daily -5.54%
06:47AM  Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive
Mar-26-18 05:13PM  9 Stocks Moving In Monday's After-Hours Session Benzinga
04:05PM  AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients GlobeNewswire
Mar-21-18 08:30AM  Todays Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology ACCESSWIRE
Mar-20-18 07:40AM  Wired News Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA ACCESSWIRE
07:40AM  Analysis: Positioning to Benefit within AnaptysBio, MoSys, CONMED, Franklin Financial Network, Hersha Hospitality Trust, and Inovalon Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-18-18 10:31AM  2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing? Motley Fool
Mar-15-18 07:31AM  Better Know Biotech: 3 Highfliers That Ought to Be on Your Radar Motley Fool
Mar-06-18 02:02PM  AnaptysBio Gears Up For an Eventful Year Motley Fool
Mar-05-18 04:15PM  AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones GlobeNewswire -7.45%
Feb-26-18 09:25AM  George Soros Just Bought These 2 Biotech Stocks. Should You? Motley Fool
Feb-17-18 05:00PM  AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Feb-07-18 04:44PM  Here's Why AnaptysBio, Inc. Stock Surged on Wednesday Motley Fool +9.36%
06:30AM  AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Jan-18-18 07:40AM  Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC Discovering Underlying Factors of Influence GlobeNewswire
Jan-02-18 08:00AM  The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt Zacks
06:30AM  AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference GlobeNewswire
Dec-29-17 02:40PM  5 Best Performing IPOs of 2017 Zacks
Dec-28-17 08:23AM  The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical Zacks
Nov-07-17 06:00AM  AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates GlobeNewswire
Nov-06-17 04:15PM  AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results GlobeNewswire
Oct-31-17 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Londei MarcoChief Medical OfficerNov 27Option Exercise6.9346,202320,18068,579Dec 02 04:29 PM
Suria HamzaPresident, CEONov 22Option Exercise1.1210,00011,20027,636Nov 25 04:49 PM
Suria HamzaPresident, CEOJun 10Sale73.7622,4281,654,35017,636Jun 12 05:00 PM
Londei MarcoChief Medical OfficerJun 04Option Exercise0.7010,0607,04232,437Jun 05 05:54 PM
Londei MarcoChief Medical OfficerJun 04Sale73.0610,060734,96222,377Jun 05 05:54 PM
Suria HamzaPresident, CEOApr 17Option Exercise1.1210,00011,20040,064Apr 18 06:34 PM
Londei MarcoChief Medical OfficerJan 15Option Exercise6.9319,075132,19041,452Jan 16 07:09 PM
Londei MarcoChief Medical OfficerJan 15Sale69.8819,0751,332,88222,377Jan 16 07:09 PM
Suria HamzaPresident, CEOJan 14Option Exercise1.1240,00044,80070,064Jan 16 07:11 PM
Suria HamzaPresident, CEOJan 14Sale70.7940,0002,831,53230,064Jan 16 07:11 PM
Londei MarcoChief Medical OfficerDec 17Option Exercise5.2630,048158,094174,925Dec 18 09:48 PM
Londei MarcoChief Medical OfficerDec 17Sale66.7630,0482,005,856144,877Dec 18 09:48 PM